Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease.

Wang JM, Singh C, Liu L, Irwin RW, Chen S, Chung EJ, Thompson RF, Brinton RD.

Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6498-503. doi: 10.1073/pnas.1001422107. Epub 2010 Mar 15. Erratum in: Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11145.

2.

Regeneration in a degenerating brain: potential of allopregnanolone as a neuroregenerative agent.

Wang JM, Irwin RW, Liu L, Chen S, Brinton RD.

Curr Alzheimer Res. 2007 Dec;4(5):510-7. Review.

5.

Regenerative potential of allopregnanolone.

Wang JM, Liu L, Irwin RW, Chen S, Brinton RD.

Brain Res Rev. 2008 Mar;57(2):398-409. Epub 2007 Sep 14. Review.

PMID:
17931704
6.

Allopregnanolone as regenerative therapeutic for Alzheimer's disease: translational development and clinical promise.

Irwin RW, Brinton RD.

Prog Neurobiol. 2014 Feb;113:40-55. doi: 10.1016/j.pneurobio.2013.08.004. Epub 2013 Sep 14. Review.

PMID:
24044981
7.

[Neurochemical mechanisms of a novel Alzheimer's disease therapeutics on improvement of cognition and depressive behavior].

Shioda N, Yamamoto Y, Han F, Moriguchi S, Fukunaga K.

Yakugaku Zasshi. 2011 Apr;131(4):505-11. Review. Japanese.

8.

Neurogenesis in mouse models of Alzheimer's disease.

Chuang TT.

Biochim Biophys Acta. 2010 Oct;1802(10):872-80. doi: 10.1016/j.bbadis.2009.12.008. Epub 2010 Jan 6. Review.

9.

Neurogenesis-based epigenetic therapeutics for Alzheimer's disease (Review).

Li X, Bao X, Wang R.

Mol Med Rep. 2016 Aug;14(2):1043-53. doi: 10.3892/mmr.2016.5390. Epub 2016 Jun 10. Review.

PMID:
27314984
10.

Exercise as a pro-cognitive, pro-neurogenic and anti-inflammatory intervention in transgenic mouse models of Alzheimer's disease.

Ryan SM, Kelly ÁM.

Ageing Res Rev. 2016 May;27:77-92. doi: 10.1016/j.arr.2016.03.007. Epub 2016 Mar 31. Review.

PMID:
27039886
11.

Behavior of neural stem cells in the Alzheimer brain.

Waldau B, Shetty AK.

Cell Mol Life Sci. 2008 Aug;65(15):2372-84. doi: 10.1007/s00018-008-8053-y. Review.

12.

Neurosteroids as regenerative agents in the brain: therapeutic implications.

Brinton RD.

Nat Rev Endocrinol. 2013 Apr;9(4):241-50. doi: 10.1038/nrendo.2013.31. Epub 2013 Feb 26. Review.

PMID:
23438839
13.

Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's disease.

Crawley JN.

Cell Mol Life Sci. 2008 Jun;65(12):1836-41. doi: 10.1007/s00018-008-8158-3. Review.

14.

Selenomethionine promoted hippocampal neurogenesis via the PI3K-Akt-GSK3β-Wnt pathway in a mouse model of Alzheimer's disease.

Zheng R, Zhang ZH, Chen C, Chen Y, Jia SZ, Liu Q, Ni JZ, Song GL.

Biochem Biophys Res Commun. 2017 Mar 25;485(1):6-15. doi: 10.1016/j.bbrc.2017.01.069. Epub 2017 Jan 19. Review.

PMID:
28109879
15.

The impact of ginsenosides on cognitive deficits in experimental animal studies of Alzheimer's disease: a systematic review.

Sheng C, Peng W, Xia ZA, Wang Y, Chen Z, Su N, Wang Z.

BMC Complement Altern Med. 2015 Oct 24;15:386. doi: 10.1186/s12906-015-0894-y. Review.

16.
17.

Toxin-Induced Experimental Models of Learning and Memory Impairment.

More SV, Kumar H, Cho DY, Yun YS, Choi DK.

Int J Mol Sci. 2016 Sep 1;17(9). pii: E1447. doi: 10.3390/ijms17091447. Review.

18.

Neural stem/progenitor cells in Alzheimer's disease.

Tincer G, Mashkaryan V, Bhattarai P, Kizil C.

Yale J Biol Med. 2016 Mar 24;89(1):23-35. eCollection 2016 Mar. Review.

19.

Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders.

Irwin RW, Solinsky CM, Brinton RD.

Front Cell Neurosci. 2014 Jul 30;8:203. doi: 10.3389/fncel.2014.00203. eCollection 2014. Review.

20.

Experimental sleep deprivation as a tool to test memory deficits in rodents.

Colavito V, Fabene PF, Grassi-Zucconi G, Pifferi F, Lamberty Y, Bentivoglio M, Bertini G.

Front Syst Neurosci. 2013 Dec 13;7:106. doi: 10.3389/fnsys.2013.00106. Review.

Supplemental Content

Support Center